血清肿瘤标记物联合检测在肺癌诊断中的意义

Clinical Value of Combined Detection of Three Serum Tumor Markers in Diagnosis of Lung Cancer

目的研究肺癌及肺部良性疾病患者血清癌胚抗原(CEA),细胞角质蛋白(Cyfra21-1),神经特异性烯醇化酶(NSE)的水平,探讨其在肺癌诊断与鉴别诊断中的价值。方法采取血清标本128份,其中肺部良性病变组36例,肺恶性肿瘤92例,CEA、Cyfra21-1采用酶联免疫法检测,NSE采用放射免疫法检测,结果以(x±s)表示,进行统计分析。结果肺癌组CEA、Cyfra21-1测定值明显高于肺良性病变组(P<0.05)。3项肿瘤标记物测定水平与病理类型有关,血CEA以腺癌最高,血NSE以小细胞肺癌最高,血Cyfra21-1以鳞癌最高。结论3项肿瘤标记物联合检测有利于肺癌的诊断与鉴别诊断。

Objective To investigate the levels of serum carcinoembryonic antigen （CEA） , neuron-specific enolase （NSE） and cytokeratin fragment Antigen 21-1 （Cyfra21-1） in patients with lung cancer or benign lung diseases,and evaluate its differential clinical diagnostic value in lung cancer. Methods CEA and Cyfra21-1 were determined with enzyme-linked immunosorbent assay（ELISA） and NSE with immunoradiometric assay（IRMA） in 92 cases with lung cancer and 36 cases with benign diseases. The data were analyzed by t-test. Results The serum levels of CEA and Cyfra21-1 in patients with lung cancer were significantly higher than that in those with begin lung diseases respectively（ P 〈0.05 ）. The serum levels of CEA ,NSE and Cyfra21-1 were related to the type of pathology. The highest serum levels of CEA appeared in adenocarcinoma, NSE in small cell carcinoma,and Cyfra21-1 in squamous cell carcinoma. Conclusions Combined determination of serum levels of CEA,NSE and Cyfra21-1 is helpful in the diagnosis and differential diagnosis of lung cancer.